Cara Therapeutics reported $28.19M in Current Liabilities for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Liabilities Change
Acadia Pharmaceuticals ACAD:US USD 116.57M 1.11M
Acelrx Pharmaceuticals ACRX:US USD 15.65M 2.04M
Cara Therapeutics CARA:US USD 28.19M 7.02M
Chugai Pharma 4519:JP JPY 423.73B 54.76B
Depomed DEPO:US USD 92.3M 23.85M
Endo International Ordinary Shares ENDP:US USD 543.05M 638.62M
Halozyme Therapeutics HALO:US USD 109.38M 90.13M
Horizon Pharma HZNP:US USD 860.61M 69.55M
JAZZ PHA JAZZ:US USD 812.95M 107.51M
Pacira Pharmaceuticals PCRX:US USD 131.53M 1.65M
Pain Therapeutics PTIE:US USD 8.31M 414K
Revance Therapeutics RVNC:US USD 74.73M 2.49M
Supernus Pharmaceuticals SUPN:US USD 725.99M 9.55M
Teva Pharmaceutical Industries TEVA:US USD 11.53B 538M
Vanda Pharmaceuticals VNDA:US USD 92.62M 4.22M